Financiere des Professionnels Fonds d investissement inc. Trims Position in STERIS plc $STE

Financiere des Professionnels Fonds d investissement inc. cut its position in STERIS plc (NYSE:STE) by 19.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 37,295 shares of the medical equipment provider’s stock after selling 9,106 shares during the quarter. Financiere des Professionnels Fonds d investissement inc.’s holdings in STERIS were worth $9,455,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Deutsche Bank AG increased its stake in shares of STERIS by 34.8% in the fourth quarter. Deutsche Bank AG now owns 613,322 shares of the medical equipment provider’s stock worth $155,489,000 after purchasing an additional 158,243 shares in the last quarter. Focus Partners Advisor Solutions LLC increased its stake in shares of STERIS by 27.2% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 5,819 shares of the medical equipment provider’s stock worth $1,475,000 after purchasing an additional 1,246 shares in the last quarter. Advocacy Wealth Management LLC purchased a new stake in shares of STERIS in the fourth quarter worth $626,000. Waddell & Associates LLC increased its stake in shares of STERIS by 148.6% in the fourth quarter. Waddell & Associates LLC now owns 2,220 shares of the medical equipment provider’s stock worth $563,000 after purchasing an additional 1,327 shares in the last quarter. Finally, Cerity Partners LLC increased its stake in shares of STERIS by 116.7% in the fourth quarter. Cerity Partners LLC now owns 209,923 shares of the medical equipment provider’s stock worth $53,220,000 after purchasing an additional 113,070 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at STERIS

In related news, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the completion of the transaction, the director directly owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. The trade was a 3.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel A. Carestio sold 3,054 shares of STERIS stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $214.64, for a total transaction of $655,510.56. Following the transaction, the chief executive officer directly owned 65,021 shares of the company’s stock, valued at approximately $13,956,107.44. This represents a 4.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,909 shares of company stock valued at $1,257,083 in the last quarter. 1.07% of the stock is owned by company insiders.

STERIS Price Performance

STE stock opened at $207.71 on Thursday. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The company has a fifty day simple moving average of $216.60 and a two-hundred day simple moving average of $237.99. The firm has a market capitalization of $20.27 billion, a P/E ratio of 26.19 and a beta of 0.93.

STERIS (NYSE:STE) last released its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same quarter last year, the business earned $2.74 EPS. STERIS’s revenue for the quarter was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts anticipate that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be given a dividend of $0.63 per share. The ex-dividend date is Monday, June 8th. This represents a $2.52 annualized dividend and a yield of 1.2%. STERIS’s dividend payout ratio (DPR) is 31.78%.

Analyst Ratings Changes

Several equities analysts recently weighed in on STE shares. KeyCorp cut their target price on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and set a $270.00 target price on shares of STERIS in a research note on Thursday, May 21st. Weiss Ratings cut shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Finally, Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, STERIS currently has a consensus rating of “Moderate Buy” and an average target price of $278.00.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.